Ocugen (OCGN) to Release Quarterly Earnings on Friday

Ocugen (NASDAQ:OCGN - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect Ocugen to post earnings of ($0.06) per share for the quarter.

Ocugen (NASDAQ:OCGN - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Price Performance

NASDAQ OCGN traded down $0.02 during trading hours on Friday, reaching $0.67. 3,191,838 shares of the company's stock were exchanged, compared to its average volume of 4,556,657. The firm has a fifty day moving average of $0.66 and a 200-day moving average of $0.77. Ocugen has a one year low of $0.52 and a one year high of $2.06. The stock has a market cap of $196.80 million, a PE ratio of -3.74 and a beta of 4.21. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Ocugen in a research note on Thursday, March 6th. Chardan Capital raised their price objective on shares of Ocugen from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Thursday, March 6th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.